Released May 9, 2023, after the close
10-Q filed May 9, 2023, 39 days after period end · 0000320017-23-000028
Q1 2022 · 10-Q
Revenue$0.00$0.00 no prior Q1 2021 on fileno prior Q4 2021 on file
Net Income-$6.19M-$6.19M N/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$0.77-$0.77 N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$6,844,000N/M
Operating Cash Flow-$8,196,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 |
|---|---|---|---|---|
| Revenue | $0.00 | — | — | — |
| Net Income | -$6.19M | -$4.23M | -$8.06M | -$3.99M |
| EPS Diluted | -$0.77 | -$1.05 | -$0.19 | -$0.38 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lisata Therapeutics, Inc. · CIK 320017 · Engraved from SEC EDGAR